Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025
Cytek Biosciences (Nasdaq: CTKB) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close. The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day, where management will discuss quarterly results, business developments, and future outlook. Investors can access the live webcast through the company's investor relations website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 6 agosto 2025, dopo la chiusura dei mercati. La società terrà una conference call e una webcast alle 13:30 PT / 16:30 ET dello stesso giorno, durante le quali il management discuterà i risultati trimestrali, gli sviluppi aziendali e le prospettive future. Gli investitori potranno seguire la diretta webcast tramite il sito web delle relazioni con gli investitori all'indirizzo investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 6 de agosto de 2025, después del cierre del mercado. La empresa realizará una llamada conferencia y una transmisión en vivo a las 1:30 PM PT / 4:30 PM ET del mismo día, donde la dirección discutirá los resultados trimestrales, desarrollos comerciales y perspectivas futuras. Los inversores pueden acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de la compañía en investors.cytekbio.com.
Cytek Biosciences (나스닥: CTKB)는 2025년 2분기 재무 실적 발표를 2025년 8월 6일 장 마감 후에 예정했습니다. 회사는 같은 날 오후 1:30 PT / 오후 4:30 ET에 컨퍼런스 콜과 웹캐스트를 개최하며, 경영진이 분기 실적, 사업 개발 및 향후 전망에 대해 논의할 예정입니다. 투자자들은 회사의 투자자 관계 웹사이트인 investors.cytekbio.com을 통해 생중계 웹캐스트에 접속할 수 있습니다.
Cytek Biosciences (Nasdaq : CTKB) a prévu d'annoncer ses résultats financiers du deuxième trimestre 2025 le 6 août 2025, après la clôture du marché. La société organisera une conférence téléphonique et une webdiffusion à 13h30 PT / 16h30 ET le même jour, au cours desquelles la direction présentera les résultats trimestriels, les évolutions commerciales et les perspectives futures. Les investisseurs pourront accéder à la webdiffusion en direct via le site des relations investisseurs de la société à l'adresse investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 6. August 2025, nach Börsenschluss, geplant. Das Unternehmen wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, bei denen das Management die Quartalsergebnisse, geschäftliche Entwicklungen und die zukünftige Perspektive erläutern wird. Investoren können den Live-Webcast über die Investor-Relations-Webseite der Firma unter investors.cytekbio.com verfolgen.
- None.
- None.
FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
FAQ
When will Cytek Biosciences (CTKB) report Q2 2025 earnings?
What time is the Cytek Biosciences Q2 2025 earnings call?
How can I listen to Cytek Biosciences (CTKB) Q2 2025 earnings call?
What will be discussed in Cytek Biosciences Q2 2025 earnings call?
